Biomarkers and novel PET imaging to detect neuroendocrine prostate cancer
Clin Adv Hematol Oncol. 2024 Jan-Feb;22(1):16-17.NO ABSTRACTPMID:38294736 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 31, 2024 Category: Cancer & Oncology Authors: Rahul Aggarwal Source Type: research
The Efficacy of Ketoconazole Containing Regimens in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
Clin Genitourin Cancer. 2024 Jan 10:S1558-7673(24)00005-3. doi: 10.1016/j.clgc.2024.01.003. Online ahead of print.ABSTRACTCastration resistant prostate cancer (CRPC) is a challenging subset of prostate cancer associated with an extensive metastatic profile and high mortality. Ketoconazole is a nonselective steroid 17α-hydroxylase/17,20 lyase (CYP17A1) inhibitor and is employed as a second line treatment option for CRPC with an established efficacy profile in patients. The aim of this study is to assess the efficacy of ketoconazole containing regimens for CRPC in terms of prostate specific antigen (PSA) decline rate using ...
Source: Clinical Prostate Cancer - January 31, 2024 Category: Cancer & Oncology Authors: Obaid Ur Rehman Zain Ali Nadeem Eeshal Fatima Umar Akram Hiba Imran Ali Husnain Arsalan Nadeem Waqas Rasheed Source Type: research
Patterns of metastatic spread and tumor burden in unselected cancer patients using PET imaging: Implications for the oligometastatic spectrum theory
CONCLUSION: The majority of metastatic cancer patients are characterized by either a solitary metastasis or a high tumor burden with >10 metastases, the latter was often associated with affecting a limited number of organs. These findings support both the spectrum theory of metastasis and the seed and soil hypothesis and can support in designing the next generation of clinical trials in the field of oligometastatic disease.PMID:38288311 | PMC:PMC10823052 | DOI:10.1016/j.ctro.2024.100724 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 30, 2024 Category: Cancer & Oncology Authors: Sebastian M Christ Kaspar Pohl Jonas Willmann Philip Heesen Astrid Heusel Maiwand Ahmadsei Anja K ühnis Eugenia Vlaskou Badra Urs J Muehlematter Michael Mayinger Panagiotis Balermpas Nicolaus Andratschke Nicholas Zaorsky Martin Huellner Matthias Guckenbe Source Type: research
The Ability of the STAR-CAP Staging System to Prognosticate the Risk of Subsequent Therapies and Metastases After Initial Treatment of M0 Prostate Cancer
CONCLUSIONS: The probability of receiving subsequent therapy was higher for patients undergoing surgery, while radiation therapy patients were more likely to receive treatment with intensified multimodality therapies upfront.PMID:38290900 | DOI:10.1016/j.clgc.2023.12.014 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 30, 2024 Category: Cancer & Oncology Authors: Daeun Sung Bogdana Schmidt Jonathan David Tward Source Type: research
Nomogram for predicting the overall survival and cancer-specific survival of patients with intraductal carcinoma of the prostate
CONCLUSION: We developed and verified nomogram models for the prediction of 1-, 3-, and 5-year OS and CSS in patients with IDC-P. These nomograms serve as a resource for evaluating patient prognosis, therapy, and diagnosis, ultimately improving clinical decision-making accuracy.PMID:38281261 | PMC:PMC10822789 | DOI:10.1007/s00432-023-05582-5 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 28, 2024 Category: Cancer & Oncology Authors: Yongqiang Cui Junyang Lin Dingqi Sun Hui Zhang Tongxiang Diao Qiang Fu Source Type: research
Cystic Pelvic Masses in Men: A Presentation of Uncommon Cases and a Literature Review
We present a case series of 3 male patients with different clinical symptoms (perineal pain, urinary retention and a large scrotal cyst) related to cystic lesions in the pelvic region. On all patients initial histopathological workup was unclear. All patients underwent surgery with complete resection of the tumor which revealed a broad spectrum of histopathological findings: unusual form of cystic adenocarcinoma of the prostate, malignant transformation of a dysontogenetic cyst, and finally a very rare diagnosis of a malignant tumor of the Cowper gland. This case series and literature review provide clues for a possible di...
Source: Clinical Prostate Cancer - January 28, 2024 Category: Cancer & Oncology Authors: Constantin Rieger David Pfister Lucas Kastner Marie-Lisa Eich Alexander Quaas Yuri Tolkach Axel Heidenreich Source Type: research
PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence
Clin Genitourin Cancer. 2023 Dec 21:S1558-7673(23)00277-X. doi: 10.1016/j.clgc.2023.12.011. Online ahead of print.ABSTRACTPoly (ADP-ribose) polymerase inhibitors (PARPi) represent an option in selected cases of metastatic castration-resistant prostate cancer (mCRPC). The aim of the present systematic review and meta-analysis is to evaluate the efficacy and safety of approved (Olaparib, Rucaparib) and investigational (Talazoparib, Niraparib, Veliparib) PARPi in mCRPC patients. Three databases were queried for studies analyzing oncological outcomes and adverse events of mCRPC patients receiving PARPi. Primary outcome was a P...
Source: Clinical Prostate Cancer - January 28, 2024 Category: Cancer & Oncology Authors: Francesco Ditonno Alberto Bianchi Sarah Malandra Antonio Benito Porcaro Emanuela Fantinel Riccardo Negrelli Matteo Ferro Michele Milella Matteo Brunelli Riccardo Autorino Maria Angela Cerruto Alessandro Veccia Alessandro Antonelli Source Type: research
Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: Real-world data from the E < sup > 2 < /sup > -RADIatE OligoCare cohort
CONCLUSION: Metastases-directed stereotactic body radiotherapy had no negative impact on global HRQoL within the first six months after treatment.PMID:38274388 | PMC:PMC10808936 | DOI:10.1016/j.ctro.2023.100715 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 26, 2024 Category: Cancer & Oncology Authors: Ren ée Bultijnck Mieke Van Hemelrijck Val érie Fonteyne Lorenzo Livi Barbara Alicja Jereczek-Fossa Hossein Hemmatazad Michael Mayinger Heike Peulen Luc Verbeke Sara Ramella Pablo Castro Pelagia Tsoutsou Karin Stellamans Adnan Shaukat Miha Orazem Paul Je Source Type: research
Oridonin attenuated human PC-3 cell activity by modulating the Wnt/ β-catenin signaling
CONCLUSIONS: Oridonin inhibited proliferation and induced apoptosis in PC-3 cells, with the findings suggesting that it acted via the Wnt/β-catenin pathway to exert its effects. This study demonstrates that ORD may impact PC.PMID:38269477 | DOI:10.17219/acem/175519 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 25, 2024 Category: Cancer & Oncology Authors: Shuling Zhang Annamalai Vijayalakshmi Lingjun Meng Source Type: research
Cerebral and Muscular Metastases From Prostate Adenocarcinoma Initially Depicted by 177 Lu-PSMA SPECT/CT
Clin Nucl Med. 2024 Mar 1;49(3):262-264. doi: 10.1097/RLU.0000000000005050. Epub 2024 Jan 24.ABSTRACTCerebral and muscular metastases from prostatic adenocarcinoma occur rarely. Patients who develop such metastatic pattern exhibit noticeable symptoms. Herein, we present a 68-year-old man diagnosed with metastatic castrate-resistant prostate cancer. The patient received multiple 177 Lu-PSMA cycles. After the last cycle, a posttreatment SPECT/CT suggested disease progression with uncommon metastatic pattern in the right temporal brain lobe and muscles. 68 Ga-PSMA PET/CT and brain MRI confirmed these findings. Surprisingly, t...
Source: Clinical Prostate Cancer - January 25, 2024 Category: Cancer & Oncology Authors: Akram Al-Ibraheem Feras Istatieh Ahmed Saad Abdlkadir Mohammed Shahait Fadi Khreish Source Type: research
Incidental Prostate-Specific Membrane Antigen-Avid Vestibular Schwannoma Detected on 68 Ga-Prostate-Specific Membrane Antigen PET/CT
Clin Nucl Med. 2024 Mar 1;49(3):234-236. doi: 10.1097/RLU.0000000000005028. Epub 2024 Jan 25.ABSTRACTA 62-year-old man was referred for a 68 Ga-prostate-specific membrane antigen (PSMA) PET/CT scan for newly diagnosed prostate cancer (ISUP grade 5), on the background of left vestibular schwannoma treated with surgical excision 25 years ago. PSMA PET study confirmed the presence of PSMA-avid malignancy in the left prostate lobe with no evidence of PSMA-avid nodal or distant metastasis. An incidental PSMA-avid focus (SUV max , 4.3) was identified in the region of the left cerebellopontine angle, which corresponded to a homog...
Source: Clinical Prostate Cancer - January 25, 2024 Category: Cancer & Oncology Authors: Jeffrey Chen Paul Bui Chuong Bui Robert Mansberg Source Type: research
Contribution of 68 Ga-DOTA-FAPI-04 PET/CT to Prostate Cancer Imaging : Complementary Role in PSMA-Negative Cases
CONCLUSIONS: FAPI PET imaging seems to have a potential to contribute PSMA PET imaging with FAPI positivity in more than half of PSMA-negative cases. Also, FAPI-targeted radionuclide therapy may be a promising method in patients resistant to PSMA-targeted therapy.PMID:38271254 | DOI:10.1097/RLU.0000000000005064 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 25, 2024 Category: Cancer & Oncology Authors: Nurhan Erg ül Tevfik Fikret Çermik G öksel Alçın Esra Arslan Özge Erol Fenercioğlu Ediz Beyhan Rahime Şahin Mehmnet Can Balo ğlu Sevim Baykal Koca R üştü Türkay U ğur Yücetaş Source Type: research
PSMA Avidity in the Heterotropic Ossification-An Incidental Finding on PSMA PET/CT
Clin Nucl Med. 2024 Mar 1;49(3):e118-e119. doi: 10.1097/RLU.0000000000005054. Epub 2024 Jan 24.ABSTRACTThe upregulations of prostate-specific membrane antigen (PSMA) antigen are used for the presence of prostate cancer. However, published literature shows incidentally detected PSMA uptake in various nonprostatic benign and malignant conditions, which led to questioning the specificity of PSMA-targeted PET. In present case, we highlighted the abnormal PSMA expression in the benign bone abnormality.PMID:38271263 | DOI:10.1097/RLU.0000000000005054 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 25, 2024 Category: Cancer & Oncology Authors: Tarun Kumar Jain Mansha Vohra Bhawani Shankar Sharma Shikha Dhal Lalit Mohan Sharma Source Type: research
Evaluation of Delivered Doses in Proton Beam Therapy for Prostate Cancer Using Positron Emission Tomography/Computed Tomography Imaging
CONCLUSIONS: PET/CT exhibited potential as a valuable tool for validating the irradiated dose to organs at risk.PMID:38272762 | DOI:10.1016/j.clon.2024.01.011 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 25, 2024 Category: Cancer & Oncology Authors: S Shiraishi M Yamanaka T Murai K Tokuuye Source Type: research
The European Network for the Study of Adrenal Tumors staging system (2015): a United States validation
CONCLUSION: The accuracy of mENSAT is virtually the same as that of AJCC in predicting CSM (74.7 vs. 74.5%) and OM (73.7 vs. 73.5%). However, calibration is lower for mENSAT than for AJCC. In consequence, no obvious benefit appears to be associated with the use of mENSAT relative to AJCC in United States ACC patients.PMID:38266758 | DOI:10.1210/clinem/dgae047 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 24, 2024 Category: Cancer & Oncology Authors: Letizia Maria Ippolita Jannello Reha-Baris Incesu Simone Morra Lukas Scheipner Andrea Baudo Mario de Angelis Carolin Siech Zhe Tian Jordan A Goyal Stefano Luzzago Francesco A Mistretta Matteo Ferro Fred Saad Shahrokh F Shariat Felix K H Chun Alberto Briga Source Type: research
